Lundbeck hits record for H1

In the first half of the year, the pharmaceutical company Lundbeck has generated revenue of more than ten billion Danish kroner. Photo: Ida Guldbæk Arentsen/Ritzau Scanpix
Several of the drugs produced by the Danish pharmaceutical company Lundbeck are doing well. This is one of the reasons why the company has seen its profits grow by 61 per cent during the first half of 2023, according to Lundbeck’s H1 report on Wednesday. The company has earned DKK 1.5 billion over the six months. One of the newer drugs that Lundbeck has high hopes for is the migraine drug Vyepti. The product has almost seen a doubling in sales during the period with a turnover of DKK 757 million. This has contributed to a total turnover of DKK 9.98 billion, a record for the period. /ritzau/